drugset / Trial / NCT02072824

A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

NCT02072824

Phase 3 Completed 175 enrolled Viatris Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to evaluate the effectiveness of 2 doses of pregabalin to reduce seizure frequency as an add on therapy in pediatric subjects 1 month to \<4 years of age with refractory partial onset seizures. It is hypothesized that both doses of pregabalin will demonstrate superior efficacy when compared to placebo by reducing the partial onset seizure frequency and that pregabalin will be safe and well tolerated.

Timeline

Start
2014-09-16
Primary completion
2018-03-13
Completion
2018-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 7 mg/kg
Subject Pregabalin Small molecule 14 mg/kg

Indications